Abbott Laboratories (ABT)
What's Backing Abbott's Established Pharmaceuticals Division Growth
ABT's EPD growth is fueled by emerging-market strength, broad branded generics and healthcare demand, with biosimilars adding opportunities.
Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?
Abbott's Medical Devices growth, EPD momentum and improving Nutrition support its outlook, but China risks, costs and valuation warrant caution.
Here's How ABT Broadens Diagnostics Growth Base With Oncology Expansion
Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.
Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) currently trades at $105.70, while the Street's consensus price target sits at $118.42, implying roughly 12% of upside.
These 3 Companies Reported Record Results and Raised Guidance
Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends
ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch.
Is Abbott Stock Attractive After Its Earnings and Guidance Update?
Abbott Laboratories ABT has a stronger earnings setup after a second-quarter beat and a higher profit outlook. The question is whether that improvement is enough to justify buying the stock with valuation upside looking limited.
Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher
Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Abbott Laboratories (NYSE:ABT) both recently posted earnings that show two healthcare giants moving in opposite strategic directions.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott: Bear Trap Over, With Richer Return Prospects
ABT's diversified diagnostics/nutrition/medtech segments drive multi-pronged growth prospects, as the management targets a +7% organic growth rate. The recent EXAS acquisition introduces balance sheet/bottom-line risks, albeit with the new Cancer Diagnostic segment delivering double-digit growth rates. The prior meltdown unlocks the cheap valuations, the richer dividend yields, and the excellent upside potential to my bull-case LTPT of $139.
ABT Q2 Earnings Call Flags Stronger Second-Half Setup
Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.
